Acute Lymphocytic Leukemia clinical trials

Explore recruiting acute lymphocytic leukemia clinical trials.

Recruiting acute lymphocytic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Lymphocytic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Spain, Italy, Austria, Poland, Greece, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1 Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemia

France, Austria, Netherlands, Spain, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Ireland, Greece, Poland, Denmark, Belgium, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Acute Lymphocytic Leukemia trials by city

Acute Lymphocytic Leukemia in Toronto Acute Lymphocytic Leukemia in Vancouver Acute Lymphocytic Leukemia in Montreal Acute Lymphocytic Leukemia in Calgary Acute Lymphocytic Leukemia in Edmonton Acute Lymphocytic Leukemia in Ottawa Acute Lymphocytic Leukemia in Winnipeg Acute Lymphocytic Leukemia in Quebec City Acute Lymphocytic Leukemia in Hamilton Acute Lymphocytic Leukemia in Kitchener Acute Lymphocytic Leukemia in London Acute Lymphocytic Leukemia in Halifax Acute Lymphocytic Leukemia in New York Acute Lymphocytic Leukemia in Los Angeles Acute Lymphocytic Leukemia in Chicago Acute Lymphocytic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease